ABIVAX Logo

ABIVAX

ABVX | PA

Overview

Corporate Details

ISIN(s):
FR0012333284 (+1 more)
LEI:
969500D8TMNB184OJU95
Country:
France
Address:
7 BOULEVARD HAUSSMANN, 75009 PARIS
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Abivax is a clinical-stage biotechnology company that develops therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. The company's core innovation lies in its novel approach to microRNA biology. Its lead drug candidate, obefazimod, is a first-in-class, orally administered small molecule designed to enhance the expression of miR-124, a natural regulator of the inflammatory response. Obefazimod is in late-stage clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Abivax's pipeline includes exploring obefazimod for other inflammatory indications and developing follow-on compounds from its proprietary chemical library.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for ABIVAX. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-13 18:00
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
French 20.7 KB
2025-08-11 15:21
Major Shareholding Notification
Franchissement de seuil
French 111.2 KB
2025-08-11 15:16
Major Shareholding Notification
Franchissement de seuils
French 117.2 KB
2025-08-11 11:11
Major Shareholding Notification
Franchissement de seuil
French 99.3 KB
2025-07-28 22:15
Share Issue/Capital Change
Abivax Announces Closing of $747.5 Million Public Offering
English 15.0 KB
2025-07-25 08:00
Share Issue/Capital Change
Abivax Announces Full Exercise of Underwriters Option to Purchase Additional AD…
English 15.2 KB
2025-07-24 07:30
Share Issue/Capital Change
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur …
French 11.3 KB
2025-07-23 22:15
Prospectus
Abivax annonce le lancement dune offre au public
French 43.8 KB
2025-07-22 22:06
Earnings Release
Abivax annonce des resultats positifs de phase 3 pour les deux essais d'inducti…
French 104.2 KB
2025-07-17 18:00
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
French 20.7 KB
2025-06-19 18:00
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
French 20.7 KB
2025-06-11 22:00
Post-Annual General Meeting Information
Abivax Announces Results of its June 6, 2025 Annual General Meeting
English 106.1 KB
2025-06-11 22:00
Post-Annual General Meeting Information
Abivax annonce les résultats de son Assemblée Générale du 6 juin 2025
French 81.2 KB
2025-06-11 22:00
Post-Annual General Meeting Information
Abivax Announces Results of its June 6, 2025 Annual General Meeting
English 10.1 KB
2025-06-10 15:06
Major Shareholding Notification
Franchissements de seuils
French 130.6 KB

Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ABIVAX via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-11 N/A Other Buy 319,107 N/A
2024-03-01 N/A Other Buy 7,000 91,557.90 EUR
2023-12-19 N/A Other Sell 50,000 482,500.00 EUR
2023-12-11 N/A Other Sell 2,062 19,382.80 EUR
2023-11-13 N/A Other Buy 4 39.84 EUR
2023-07-13 N/A Other Sell 192,781 3,101,480.01 EUR
2023-03-27 N/A Other Other 38,461 249,996.50 EUR
2023-02-27 N/A Other Other 1,535,000 9,977,500.00 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN
Adocia Logo
Developing novel drug formulations for metabolic diseases like diabetes and obesity for out-licensing.
France ADOC